Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Camera pill after negative scope could speed up bleeding diagnosis

NCT ID NCT05108844

Diagnosis Sponsor: University of Alberta Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether giving patients a tiny camera pill (video capsule endoscopy) right after a negative stomach scope can find the source of upper gut bleeding faster than the usual approach. About 70 adults with signs of bleeding but no cause found on initial gastroscopy will be randomly assigned to early capsule or standard care. The goal is to see if this speeds diagnosis, cuts hospital stays, and reduces the number of procedures needed.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
videocapsule endoscopy (a pill-sized camera swallowed to view the small intestine)
What this could lead to
If successful, this approach could help doctors find the source of bleeding faster and reduce the number of procedures and hospital stays.
What could go wrong
This is a small, early-stage trial with only 70 participants, so results may not apply to everyone. The capsule may not always find the bleeding source, and there is a small risk of capsule retention or other adverse events.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 70 people

The number the study aims to enrol. It can still change while the study runs.

Started

Sep 2021

Expected to finish

Nov 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 90 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age ≥ 18 years * New onset of acute gastrointestinal bleeding defined as: 1. The presence of melena/maroon stool on physical exam OR history of melena/maroon stool within 48 hours of emergency room presentation PLUS 2. Hemoglobin drop of ≥ 20 g/L from patient's baseline * Have capacity to consent * Hemodynamically stable (i.e. blood pressure \>100/60 or pulse \<110 at the time of consent) * Initial gastroscopy negative for active bleeding or potential bleeding source Exclusion Criteria: * Inability to provide consent due to lack of capacity, language barrier or other reasons * Pregnant women * Prior history of small bowel surgery * Prior history of Crohn's disease * Prior history of small bowel or colonic strictures * Prior history of abdominal radiation

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Small bowel bleeding are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Small bowel bleeding

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • University of Alberta Hospital

    RECRUITING

    Edmonton, Alberta, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.